Premature Ovarian Failure (Genetic and Physiopathologic Analysis)

NCT00780897 | Unknown

• 1 other identifier: P040801
• Study Type: observational
• Target: 87
• Locations: 1 country
• Sites: 1

Brief Summary

Premature Ovarian Failure (POF), syndrome observed in young woman, present consequences on hormonal and leads at definitive infertility. It's a rare and complex syndrome and for this reason, we propose to initiate a collaborative team network to understand better his genetic and physiopathology. We are going to realize a global study of this syndrome with clinical and fundamentals approaches. We wish that this project allows us to understand better the physiopathology of this rare disease. Finally, POF responsible genes identification is the base for future development of therapeutics approaches.

Conditions

Premature Ovarian Failure

Keywords

PREMATURE OVARIAN FAILURE (POF); GENETIC ANALYSIS; PHYSIOPATHOLOGIC ANALYSIS

Study Arms (2)

1

POF patients; 18 years \<Age\> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;

2

Control Group No POF patients; Benign ovarian pathology; 18 years \<Age\> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography

Eligibility Criteria

• Age: 18 Years - 39 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

POF patients \& controls

You may qualify if:

• Experimental group:
• years \<Age\> 39 years
• Patient with amenorrhea since at least 3 months
• Patient with at least 1 FSH dosage \> 30 mUI/L
• Patients between 40 and 45 years old with hormonal results indicating a POF declared before 39 years old will be included.
• Informed Consent Form Signature
• Control group:
• years \<Age\> 39 years
• Patient having a benign ovarian pathology justifying an ovarian surgery
• Informed Consent Form Signature

You may not qualify if:

• Not applicable

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Groupe Hopitalier Pitié-Salpêtrière

Paris, 75013, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

One ovarian biopsy during the protocol to evaluate ovocytes number and transcriptome analysis.

MeSH Terms

Conditions

Primary Ovarian Insufficiency

Condition Hierarchy (Ancestors)

Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Officials

• Philippe Touraine, MD, PhD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Philippe Touraine, MD, PhD

CONTACT

+33 1 42 16 02 11; philippe.touraine@psl.aphp.fr

Study Design

• Study Type: observational
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: October 27, 2008
• First Posted: October 28, 2008
• Study Start: March 1, 2005
• Primary Completion: March 1, 2009
• Study Completion: March 1, 2009
• Last Updated: October 28, 2008

Record last verified: 2008-10

Locations

FR (1)